Anticancer Res 23(3B):24252433 Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J, Powis G (1996) Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia
This phase II trial demonstrates that enobosarm, a selective AR modulator, shows anti-tumour activity and clinical benefit in women in postmenopause with ER-positive, HER2-negative and AR-positive advanced breast cancer, supporting further investigation of AR activation as a therapeutic strategy
Cabello-Rivera, D., Sarmiento-Soto, H., Lpez-Barneo, J
The short answer is yes, but the context is vital
The subtype is usually determined when the histopathologist examines the excised tissue under the microscope
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications